IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
22. Januar 2025 08:00 ET
|
IMMvention Therapeutix, Inc.
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a...
Rising Incidence and Newborn Screening Programs Spur Rapid Growth in Sickle Cell Anemia Diagnostics
13. Januar 2025 05:39 ET
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Sickle Cell Anemia Testing and Screening Market by Technology, by Age Group, End-User, and By Region" report has been added to ...
Kanglin Biotechnology Announces $20 Million Series A Financing to Advance the Development of Gene Therapies
25. November 2024 07:00 ET
|
Kanglin Biotec
- Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal and favorable safety profile – - Manufacturing costs...
Sickle Cell Disease Market Reach USD 12.38 Bn by 2032, Set to Grow Remarkable CAGR of 20.00% from 2024-2032
07. November 2024 05:49 ET
|
Introspective Market Research
Mexico, Mexico City, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Introspective Market Research has published a comprehensive report on the Global Sickle Cell Disease (SCD) Market, highlighting an expected...
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose
28. Oktober 2024 12:47 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE CETTE DÉCISION...
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
28. Oktober 2024 12:47 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS...
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising Advances in Gene Therapies
28. August 2024 10:14 ET
|
Spherix Global Insights
EXTON, PA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Despite advancements in treatments, sickle cell disease and thalassemia continue to present significant challenges for patients and healthcare providers....
American Institutes for Research To Help Implement Federal Program Aimed at Increasing Access to Transformative Cell and Gene Therapy Treatments
21. August 2024 12:00 ET
|
American Institutes for Research
Arlington, Va., Aug. 21, 2024 (GLOBE NEWSWIRE) -- The American Institutes for Research (AIR) has been awarded a federal contract to help implement and monitor a new program that seeks to make...
Global Sickle Cell Anemia Testing & Screening Market Analysis and Forecast 2024-2030 - Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
14. Juni 2024 05:23 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC),...
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
10. Juni 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...